Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation
Introduction: HyperCKemia is defined as the elevation of creatine phosphokinase (CK) levels greater than 1.5 times the upper limit (CK>285 U/L), being produced by multiple causes, which vary according different populations. The main objective of the study was to know the frequency o...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/36031 |
| Aporte de: |
| id |
I10-R327-article-36031 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
creatine phosphokinase muscular diseases myositis inflammation Internal medicine Clinical medicine Rheumatology creatina fosfoquinasa enfermedades musculares miositis Inflamación Medicina Interna Clínica Médica Reumatología creatina quinase doenças musculares miosite inflamação Medicina Interna clínica médica Reumatologia |
| spellingShingle |
creatine phosphokinase muscular diseases myositis inflammation Internal medicine Clinical medicine Rheumatology creatina fosfoquinasa enfermedades musculares miositis Inflamación Medicina Interna Clínica Médica Reumatología creatina quinase doenças musculares miosite inflamação Medicina Interna clínica médica Reumatologia Saad, Emanuel José Rodríguez Ruiz, Andrés Douthat y Barrionuevo , Augusto Milanesio, Martín Flores Balverdi, Janet Riscanevo, Nadia Claudine Peñaranda, Gabriela Estefanía Novatti, Elisa Beatriz Saurit, Verónica Alvarez, Ana Cecilia Baenas, Diego Federico Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| topic_facet |
creatine phosphokinase muscular diseases myositis inflammation Internal medicine Clinical medicine Rheumatology creatina fosfoquinasa enfermedades musculares miositis Inflamación Medicina Interna Clínica Médica Reumatología creatina quinase doenças musculares miosite inflamação Medicina Interna clínica médica Reumatologia |
| author |
Saad, Emanuel José Rodríguez Ruiz, Andrés Douthat y Barrionuevo , Augusto Milanesio, Martín Flores Balverdi, Janet Riscanevo, Nadia Claudine Peñaranda, Gabriela Estefanía Novatti, Elisa Beatriz Saurit, Verónica Alvarez, Ana Cecilia Baenas, Diego Federico |
| author_facet |
Saad, Emanuel José Rodríguez Ruiz, Andrés Douthat y Barrionuevo , Augusto Milanesio, Martín Flores Balverdi, Janet Riscanevo, Nadia Claudine Peñaranda, Gabriela Estefanía Novatti, Elisa Beatriz Saurit, Verónica Alvarez, Ana Cecilia Baenas, Diego Federico |
| author_sort |
Saad, Emanuel José |
| title |
Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| title_short |
Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| title_full |
Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| title_fullStr |
Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| title_full_unstemmed |
Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation |
| title_sort |
creatine phosphokinase enzyme elevation in two third-level hospitals of córdoba: creatine phosphokinase enzyme elevation |
| description |
Introduction: HyperCKemia is defined as the elevation of creatine phosphokinase (CK) levels greater than 1.5 times the upper limit (CK>285 U/L), being produced by multiple causes, which vary according different populations. The main objective of the study was to know the frequency of hyperCKemia in two hospitals in Córdoba and its main causes.
Methods: Retrospective analytical study in two hospitals in Córdoba, Argentina, where all patients over 18 years of age who presented CK values greater than 285 U/L on at least 2 occasions in a period between 1 and 4 weeks were identified, between the years 2015 and 2017.
Results: 254 patients with hyperCKemia were identified, the majority were male (n=181, 71.3%) and their median age was 65 years (interquartile range 25-75%=50-73 years). The main causes of hyperCKemia were ischemic myopathy in 99 (39%) patients and drug-induced myopathies in 45 (17.7%), with statins being the most frequently involved drugs in 31 cases. In only 3.1% of the cases the final diagnosis was not reached. Drug-induced hyperCKemias, when compared to other causes, occurred more frequently in patients with a history of chronic kidney disease (9/45 [20%] vs 18/209 [8.6%], p = 0.025) and in non-smokers (41/45 [91.1%] vs. 157/209 [75.1%], p=0.019).
Main conclusion: 254 cases of hyperCKemia were observed, the main causes being of ischemic origin and secondary to drug use, especially statins. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/36031 |
| work_keys_str_mv |
AT saademanueljose creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT rodriguezruizandres creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT douthatybarrionuevoaugusto creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT milanesiomartin creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT floresbalverdijanet creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT riscanevonadiaclaudine creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT penarandagabrielaestefania creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT novattielisabeatriz creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT sauritveronica creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT alvarezanacecilia creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT baenasdiegofederico creatinephosphokinaseenzymeelevationintwothirdlevelhospitalsofcordobacreatinephosphokinaseenzymeelevation AT saademanueljose estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT rodriguezruizandres estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT douthatybarrionuevoaugusto estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT milanesiomartin estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT floresbalverdijanet estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT riscanevonadiaclaudine estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT penarandagabrielaestefania estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT novattielisabeatriz estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT sauritveronica estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT alvarezanacecilia estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT baenasdiegofederico estudiodelospacientesconelevaciondeenzimacreatinfosfokinasaendoshospitalesdetercerniveldelaciudaddecordobaelevaciondeenzimacreatinfosfokinasa AT saademanueljose elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT rodriguezruizandres elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT douthatybarrionuevoaugusto elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT milanesiomartin elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT floresbalverdijanet elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT riscanevonadiaclaudine elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT penarandagabrielaestefania elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT novattielisabeatriz elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT sauritveronica elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT alvarezanacecilia elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase AT baenasdiegofederico elevacaodaenzimacreatinafosfoquinaseemdoishospitaisdeterceironiveldecordobaelevacaodaenzimacreatinafosfoquinase |
| first_indexed |
2024-09-03T21:03:18Z |
| last_indexed |
2024-09-03T21:03:18Z |
| _version_ |
1809210302429921280 |
| spelling |
I10-R327-article-360312023-03-20T16:24:58Z Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba: Creatine phosphokinase enzyme elevation Estudio de los pacientes con elevación de enzima Creatinfosfokinasa en dos hospitales de tercer nivel de la ciudad de córdoba: Elevación de enzima Creatinfosfokinasa Elevação da enzima creatina fosfoquinase em dois hospitais de terceiro nível de Córdoba: Elevação da enzima creatina fosfoquinase Saad, Emanuel José Rodríguez Ruiz, Andrés Douthat y Barrionuevo , Augusto Milanesio, Martín Flores Balverdi, Janet Riscanevo, Nadia Claudine Peñaranda, Gabriela Estefanía Novatti, Elisa Beatriz Saurit, Verónica Alvarez, Ana Cecilia Baenas, Diego Federico creatine phosphokinase muscular diseases myositis inflammation Internal medicine Clinical medicine Rheumatology creatina fosfoquinasa enfermedades musculares miositis Inflamación Medicina Interna Clínica Médica Reumatología creatina quinase doenças musculares miosite inflamação Medicina Interna clínica médica Reumatologia Introduction: HyperCKemia is defined as the elevation of creatine phosphokinase (CK) levels greater than 1.5 times the upper limit (CK>285 U/L), being produced by multiple causes, which vary according different populations. The main objective of the study was to know the frequency of hyperCKemia in two hospitals in Córdoba and its main causes. Methods: Retrospective analytical study in two hospitals in Córdoba, Argentina, where all patients over 18 years of age who presented CK values greater than 285 U/L on at least 2 occasions in a period between 1 and 4 weeks were identified, between the years 2015 and 2017. Results: 254 patients with hyperCKemia were identified, the majority were male (n=181, 71.3%) and their median age was 65 years (interquartile range 25-75%=50-73 years). The main causes of hyperCKemia were ischemic myopathy in 99 (39%) patients and drug-induced myopathies in 45 (17.7%), with statins being the most frequently involved drugs in 31 cases. In only 3.1% of the cases the final diagnosis was not reached. Drug-induced hyperCKemias, when compared to other causes, occurred more frequently in patients with a history of chronic kidney disease (9/45 [20%] vs 18/209 [8.6%], p = 0.025) and in non-smokers (41/45 [91.1%] vs. 157/209 [75.1%], p=0.019). Main conclusion: 254 cases of hyperCKemia were observed, the main causes being of ischemic origin and secondary to drug use, especially statins. Introducción: Se denomina hiperCKemia a la elevación de niveles de creatinfosfoquinasa (CK) mayor a 1,5 veces el límite superior(CK>285 U/L), siendo producida por múltiples causas, que varían según las poblaciones de estudio. El objetivo principal del estudio fue conocer la frecuencia de hiperCKemia en dos hospitales de la Ciudad de Córdoba y sus principales causas. Metodología: Estudio analítico retrospectivo en dos hospitales de la ciudad de Córdoba en Argentina, donde se identificaron todos los pacientes mayores de 18 años que presentaron valores de CK mayores a 285 U/L en al menos 2 oportunidades en un período entre 1 y 4 semanas, entre los años 2015 y 2017. Resultados: Se identificaron 254 pacientes con hiperCKemia, la mayoría eran de sexo masculino (n=181, 71.3%) y su mediana de edad fue 65 años (rango intercuartil 25-75%=50-73 años). Las principales causas de hiperCKemia fueron la miopatía isquémica en 99 (39%) pacientes y las miopatías inducidas por drogas en 45 (17.7%), siendo las estatinas las drogas más frecuentemente involucradas en 31 casos. En sólo el 3.1% de los casos no se arribó al diagnóstico final. Las hiperCKemias inducidas por drogas al compararse con las otras causas, se presentaron más frecuentemente en pacientes con antecedente de enfermedad renal crónica (9/45[20%] vs 18/209[8.6%], p=0.025) y en no tabaquistas(41/45[91.1%] vs 157/209[75.1%], p=0.019) . Conclusión: Se observaron 254 casos de hiperCKemia, siendo sus principales causas de origen isquémico y secundario a consumo de fármacos, especialmente por estatinas. Introdução: HiperCKemia refere-se à elevação dos níveis de creatina quinase (CK) maior que 1,5 vezes o limite superior (CK> 285 U / L), sendo produzida por múltiplas causas, que variam de acordo com as populações estudadas. O objetivo principal do estudo foi conhecer a frequência da hiperCKemia em dois hospitais da cidade de Córdoba e suas principais causas. Métodos: Estudo analítico retrospectivo em dois hospitais da cidade de Córdoba na Argentina, onde todos os pacientes maiores de 18 anos que apresentaram valores de CK superiores a 285 U/L em pelo menos 2 ocasiões em um período entre 1 e 4 semanas foram identificados, entre os anos de 2015 e 2017. Resultados: Foram identificados 254 pacientes com hiperCKemia, a maioria do sexo masculino (n = 181, 71,3%) e a mediana de idade foi de 65 anos (intervalo interquartil 25-75%= 50-73 anos). As principais causas de hiperCKemia foram miopatia isquêmica em 99 (39%) pacientes e miopatias induzidas por medicamentos em 45 (17,7%), sendo as estatinas os medicamentos mais frequentemente envolvidos em 31 casos. Em apenas 3,1% dos casos o diagnóstico final não foi alcançado. As hiperCKemia induzidas por medicamentos, quando comparadas a outras causas, ocorreram com mais frequência em pacientes com história de doença renal crônica (9/45[20%] vs. 18/209[8,6%], p=0,025) e em não fumantes (41/45 [91,1%] vs. 157/209 [75,1%], p = 0,019). Conclusão: Foram observados 254 casos de hiperCKemia, sendo as principais causas de origem isquêmica e secundárias ao uso de drogas, principalmente estatinas. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-12-21 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text Texto texto text/html application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/36031 10.31053/1853.0605.v79.n4.36031 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. 4 (2022); 327-333 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. 4 (2022); 327-333 Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. 4 (2022); 327-333 1853-0605 0014-6722 10.31053/1853.0605.v79.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/36031/39007 https://revistas.unc.edu.ar/index.php/med/article/view/36031/39780 Derechos de autor 2022 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |